GNTbm focuses on the R&D of oral new drugs in cancer immunotherapy, including tumor microenvironment regulators (TMRs), epigenetic immunoactivators, and immune-regulating multi-kinase inhibitors.

Leveraging the FAST CGT platform to enhance the specificity, persistence, and stability of regulatory T cells, improving their ability to restore immune tolerance and suppress inflammation as a targeted alternative to non-selective, high-risk immunosuppressants for autoimmune disease treatment and transplant rejection prevention./Utilizing the FAST CGT platform enhance therapeutic efficacy, durability, and precision of MSC therapies for treating inflammatory and ischemic diseases/Integrating cell therapy R&D and clinical applications through the FAST CGT platform to accelerate the development and commercialization